Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-683-1880
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) announced its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.04. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
4 brokerages have issued 1 year target prices for Agile Therapeutics' shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Agile Therapeutics' share price to reach $3.3333 in the next year. This suggests a possible upside of 278.8% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
Has Agile Therapeutics been receiving favorable news coverage?
Media coverage about AGRX stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agile Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a decline in short interest in December. As of December 14th, there was short interest totalling 1,294,868 shares, a decline of 27.0% from the November 30th total of 1,772,743 shares. Based on an average trading volume of 299,140 shares, the days-to-cover ratio is currently 4.3 days. Currently, 5.5% of the company's stock are sold short. View Agile Therapeutics' Current Options Chain.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Northwest Biotherapeutics (NWBO), Chembio Diagnostics (CEMI), Cue Biopharma (CUE), Corvus Pharmaceuticals (CRVS), Correvio Pharma (CORV), Proteostasis Therapeutics (PTI), XOMA (XOMA), ASLAN PHARMACEU/ADR (ASLN), Sol Gel Technologies (SLGL), vTv Therapeutics (VTVT), Sierra Oncology (SRRA), Eton Pharmaceuticals (ETON), China SXT Pharmaceuticals (SXTC), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) and Evofem Biosciences (EVFM).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.16%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Life Sciences Maste Perceptive and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Which major investors are selling Agile Therapeutics stock?
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $0.88.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $30.25 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
What is Agile Therapeutics' official website?
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
